Table 3 Univariate and multivariate Cox regression analysis of overall survival in 86 patients after CRS+HIPEC
Variables | Overall survival | |||
|---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
HR(95%CI) | P | HR(95%CI) | P | |
Gender: male/female | 1.21 (0.68–2.18) | 0.517 |  |  |
Age at operation | 1.01 (0.99–1.04) | 0.400 |  |  |
Preoperative chemotherapy (no/yes) | 0.79 (0.40–1.55) | 0.489 |  |  |
Synchronous/metachronous | 0.80 (0.44–1.47) | 0.476 |  |  |
Site of original (colon/rectum) | 2.13 (1.16–3.92) | 0.015 | 1.71 (0.913–3.20) | 0.094 |
Histology (adenocarcinoma/mucinous) | 1.65 (0.92–3.00) | 0.096 |  |  |
Preoperative CEA level | 1.00 (0.99–1.01) | 0.161 |  |  |
Preoperative CA19–9 level | 1.00 (0.99–1.01) | 0.342 |  |  |
Liver metastases (no/yes) | 1.36 (0.67–2.74) | 0.397 |  |  |
HIPEC regimen (lobaplatin/non-lobaplatin) | 1.60 (0.87–2.95) | 0.134 |  |  |
Presence of ascites (no/yes) | 1.34 (0.74–2.40) | 0.335 |  |  |
PCI score | 1.01 (1.05–1.15) | < 0.001 | 1.07 (1.01–1.14) | 0.015 |
CC score (0–1/2–3) | 3.36 (1.85–6.08) | < 0.001 | 1.92 (0.96–3.83) | 0.064 |
Grade 3–4 Postoperative complication (no/yes) | 2.71 (1.48–4.94) | 0.001 | 1.86 (1.22–3.51) | 0.044 |
Leukopenia (no/yes) | 1.31 (0.61–2.83) | 0.487 |  |  |
Neutropenia (no/yes) | 1.31 (0.47–3.70) | 0.605 |  |  |
Thrombocytopenia (no/yes) | 1.45 (0.80–2.66) | 0.224 |  |  |